Literature DB >> 23460395

Comparison of abdominal MRI with diffusion-weighted imaging to 68Ga-DOTATATE PET/CT in detection of neuroendocrine tumors of the pancreas.

Christine Schmid-Tannwald1, Christoph M Schmid-Tannwald, John N Morelli, Ralph Neumann, Alexander R Haug, Nathalie Jansen, Konstantin Nikolaou, Nicolai Schramm, Maximilian F Reiser, Carsten Rist.   

Abstract

PURPOSE: The aim of the study was to evaluate contrast-enhanced MRI, diffusion-weighted MRI (DW MRI), and (68)Ga-DOTATATE positron emission tomography (PET)/CT in the detection of intermediate to well-differentiated neuroendocrine tumors (NET) of the pancreas.
METHODS: Eighteen patients with pathologically proven pancreatic NET who underwent MRI including DW MRI and PET/CT within 6 weeks of each other were included in this retrospective study. Two radiologists evaluated T2-weighted (T2w), T2w + DW MRI, T2w + contrast-enhanced T1-weighted (CE T1w) MR images, and PET/CT for NET detection. The sensitivity and level of diagnostic confidence were compared among modalities using McNemar's test and a Wilcoxon signed rank test. Apparent diffusion coefficients (ADC) of pancreatic NETs and normal pancreatic tissue were compared with Student's t test.
RESULTS: Of the NETs, 8/23 (34.8 %) and 9/23 (39.1 %) were detected on T2w images by observers 1 and 2, respectively. Detection rates improved significantly by combining T2w images with DW MRI (observer 1: 14/23 = 61 %; observer 2: 15/23 = 65.2 %; p < 0.05) or CE T1w images (observer 1: 14/23 = 61 %; observer 2: 15/23 = 65.2 %; p < 0.05). Detection rates of pancreatic NET with PET/CT (both observers: 23/23 = 100 %) were statistically significantly higher than with MRI (p < 0.05). The mean ADC value of NET (1.02 ± 0.26 × 10(-3) mm(2)/s) was statistically significantly lower than that of normal pancreatic tissue (1.48 ± 0.39 × 10(-3) mm(2)/s).
CONCLUSION: DW MRI is a valuable adjunct to T2w imaging and comparable to CE T1w imaging in pancreatic NET detection, quantitatively differentiating between NET and normal pancreatic tissue with ADC measurements. (68)Ga-DOTATATE PET/CT is more sensitive than MRI in the detection of pancreatic NET.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23460395     DOI: 10.1007/s00259-013-2371-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  37 in total

1.  Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis.

Authors:  M Papotti; M Bongiovanni; M Volante; E Allìa; S Landolfi; L Helboe; M Schindler; S L Cole; G Bussolati
Journal:  Virchows Arch       Date:  2002-03-23       Impact factor: 4.064

2.  [Quantification of immunohistochemical expression of somatostatin receptors in neuroendocrine tumors using 68Ga-DOTATATE PET/CT].

Authors:  A R Haug; G Assmann; C Rist; R Tiling; G P Schmidt; P Bartenstein; M Hacker
Journal:  Radiologe       Date:  2010-04       Impact factor: 0.635

3.  Radiolabelling DOTA-peptides with 68Ga.

Authors:  Wouter A P Breeman; Marion de Jong; Erik de Blois; Bert F Bernard; Mark Konijnenberg; Eric P Krenning
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-01-18       Impact factor: 9.236

4.  Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours.

Authors:  Rakesh Kumar; Punit Sharma; Pramod Garg; Sellam Karunanithi; Niraj Naswa; Raju Sharma; Sanjay Thulkar; Sneh Lata; Arun Malhotra
Journal:  Eur Radiol       Date:  2011-07-13       Impact factor: 5.315

5.  68Ga-DOTA-peptides versus 18F-DOPA PET for the assessment of NET patients.

Authors:  Valentina Ambrosini; Domenico Rubello; Cristina Nanni; Adil Al-Nahhas; Stefano Fanti
Journal:  Nucl Med Commun       Date:  2008-05       Impact factor: 1.690

Review 6.  Gastroenteropancreatic neuroendocrine tumors: multimodality imaging features with pathological correlation.

Authors:  Daichi Hayashi; Jaroslaw N Tkacz; Stephen Hammond; Brooke C Devenney-Cakir; Souhil Zaim; Nadia Bouzegaou; Souhila Ounadjela; Ali Guermazi
Journal:  Jpn J Radiol       Date:  2011-02-27       Impact factor: 2.374

7.  Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI.

Authors:  F L Giesel; C Kratochwil; A Mehndiratta; S Wulfert; J H Moltz; C M Zechmann; H U Kauczor; U Haberkorn; S Ley
Journal:  Eur J Radiol       Date:  2012-01-10       Impact factor: 3.528

Review 8.  Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.

Authors:  Marion De Jong; Roelf Valkema; Francois Jamar; Larry K Kvols; Dik J Kwekkeboom; Wout A P Breeman; Willem H Bakker; Chuck Smith; Stanislas Pauwels; Eric P Krenning
Journal:  Semin Nucl Med       Date:  2002-04       Impact factor: 4.446

Review 9.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

10.  Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.

Authors:  Thorsten D Poeppel; Ina Binse; Stephan Petersenn; Harald Lahner; Matthias Schott; Gerald Antoch; Wolfgang Brandau; Andreas Bockisch; Christian Boy
Journal:  Recent Results Cancer Res       Date:  2013
View more
  22 in total

Review 1.  The value of (68)Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature.

Authors:  Alireza Mojtahedi; Sanjay Thamake; Izabela Tworowska; David Ranganathan; Ebrahim S Delpassand
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-08-15

Review 2.  Peptide-based imaging agents for cancer detection.

Authors:  Xiaolian Sun; Yesen Li; Ting Liu; Zijing Li; Xianzhong Zhang; Xiaoyuan Chen
Journal:  Adv Drug Deliv Rev       Date:  2016-06-18       Impact factor: 15.470

3.  The utility of 68Gallium-DOTATATE PET/CT in the detection of von Hippel-Lindau disease associated tumors.

Authors:  Jasmine Shell; Amit Tirosh; Corina Millo; Samira M Sadowski; Yasmine Assadipour; Patience Green; Dhaval Patel; Naris Nilubol; Electron Kebebew
Journal:  Eur J Radiol       Date:  2018-11-22       Impact factor: 3.528

4.  [Gastroenteropancreatic endocrine tumors].

Authors:  C Schmid-Tannwald; C M Schmid-Tannwald; M F Reiser; F Berger
Journal:  Radiologe       Date:  2014-10       Impact factor: 0.635

Review 5.  Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2018-07-17       Impact factor: 4.512

Review 6.  Novel PET tracers: added value for endocrine disorders.

Authors:  Sébastien Bergeret; Judith Charbit; Catherine Ansquer; Géraldine Bera; Philippe Chanson; Charlotte Lussey-Lepoutre
Journal:  Endocrine       Date:  2019-03-14       Impact factor: 3.633

Review 7.  Multiparametric MR Imaging in Abdominal Malignancies.

Authors:  Antonio Luna; Shivani Pahwa; Claudio Bonini; Lidia Alcalá-Mata; Katherine L Wright; Vikas Gulani
Journal:  Magn Reson Imaging Clin N Am       Date:  2016-02       Impact factor: 2.266

8.  ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.

Authors:  M Falconi; B Eriksson; G Kaltsas; D K Bartsch; J Capdevila; M Caplin; B Kos-Kudla; D Kwekkeboom; G Rindi; G Klöppel; N Reed; R Kianmanesh; R T Jensen
Journal:  Neuroendocrinology       Date:  2016-01-05       Impact factor: 4.914

9.  Isoattenuating insulinomas at biphasic contrast-enhanced CT: frequency, clinicopathologic features and perfusion characteristics.

Authors:  Liang Zhu; Hua-Dan Xue; Hao Sun; Xuan Wang; Yong-Lan He; Zheng-Yu Jin; Yu-Pei Zhao
Journal:  Eur Radiol       Date:  2016-01-26       Impact factor: 5.315

Review 10.  [Neuroendocrine tumors of the abdomen].

Authors:  M Juchems
Journal:  Radiologe       Date:  2018-01       Impact factor: 0.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.